References
- Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768–85; PMID:15692063; http://dx.doi.org/10.1182/blood-2004-09-3502
- Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, et al. Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the european organization of research and treatment of cancer (EORTC). Blood 2007; 110:1713–22; PMID:17540844; http://dx.doi.org/10.1182/blood-2007-03-055749
- Thielens A, Vivier E, Romagne F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opinion Immunol 2012; 24:239–45; PMID:22264929; http://dx.doi.org/10.1016/j.coi.2012.01.001
- Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheumatism 2005; 52:3586–95; PMID:16255049; http://dx.doi.org/10.1002/art.21395
- Sako N, Schiavon V, Bounfour T, Dessirier V, Ortonne N, Olive D, Ram-Wolff C, Michel L, Sicard H, Marie-Cardine A, et al. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4 T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry Part A 2014; 85:869-82; PMID:25044837; http://dx.doi.org/10.1002/cyto.a.22512
- Bagot M, Moretta A, Sivori S, Biassoni R, Cantoni C, Bottino C, Boumsell L, Bensussan A. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 2001; 97:1388–91; PMID:11222384; http://dx.doi.org/10.1182/blood.V97.5.1388
- Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Blery M, Paturel C, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res 2014; 74:6060–70; PMID:25361998; http://dx.doi.org/10.1158/0008-5472.CAN-14-1456
- Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007; 26:3644–53; PMID:17530018; http://dx.doi.org/10.1038/sj.onc.1210380
- Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115:798–812; PMID:15841167; http://dx.doi.org/10.1172/JCI200524826
- Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 2013; 19:3755–63; PMID:23785046; http://dx.doi.org/10.1158/1078-0432.CCR-12-3488